Schedule 13G ownership disclosure
Syndax Pharmaceuticals Inc
Common Stock · CUSIP: 87164F105
Event date: 2024-12-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Morgan Stanley
Shares: 5,362,169 · Class: 6.3%
- Morgan Stanley & Co. LLC
Shares: 5,055,451 · Class: 5.9%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000895421-25-000232
- Form type
- SCHEDULE 13G
- Filer
- MORGAN STANLEY
- CIK
- CIK 895421
- Filed
- Feb 05, 2025
- Reporting period
- Dec 31, 2024
- Description
- Schedule 13G beneficial ownership